Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And the buying pressure above .40 has maintained...
I Think more than one NOSE knows smells a major event...
This does not happen so fast and over time so close to close
Almost a million shares in under 10 minutes jolting the PPS upwards... If you have a 15/20 minute delay... you missed it. It was that quick.
Over .40..... someone knows something and is taking a large position... (or adding)
YES YS YES YES YES
HUFF HUFF HUFF PUFF PUFF PUFF GO LITTLE LADY
20 min left in the POWER HOUR
BREAK THE 40 DAMIT
Am I missing something? It still shows under 39 cents for me?
Someone knows something....... 💰️
.39 wall.... CRUSHED.
thank you gratzie takk merci cielen danke obrigado the the major buyer at .39+
Oh SHIT! BIG end of day buyer!!!!!
They could use you in NC
Share price being taken out to 5 digits. Market makers are working HARD to suppress Elite Pharmaceuticals.
$0.388285...............
Shorty working so damn hard~! 😸😹
$DLTP baby~!
Poor 🩳s
They will lose their 👕s
Shorts are up
SHORT INTEREST
DATE SHORT INTEREST % CHANGE AVG. DAILY SHARE VOL SPLIT NEW ISSUE
09/13/2024 2,195,500 19.66 9,510,127 No No
08/30/2024 1,834,756 10.45 5,263,779 No No
08/15/2024 1,661,137 5.03 1,680,731 No No
07/31/2024 1,581,526 -9.15 1,104,152 No No
07/15/2024 1,740,762 7.08 1,819,660 No No
06/28/2024 1,625,726 4.83 1,644,172 No No
06/14/2024 1,550,791 -2.39 648,688 No No
05/31/2024 1,588,697 3.79 1,269,30
Has anyone seen the actual ELTP report from Zacks ?
Can you share in private?
Flick The Tick. Repeal The Mikah Tax !!!!!!!!!!!!!!!!!
IB_🤴🏻
Good morning WeeZuhl, Interesting post! Abuse deterrent opioids may have a future. Thanks for your insights.
No shortage again, looks like every 15 days
https://dps.fda.gov/drugshortages/activeingredient/amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-saccharate-dextroamphetamine-sulfate-tablet
Nasrat has become quite popular with the FDA guys.
They just did another walk threw and passed with flying colors
Must be the Coffee,
they keep coming back
So just for fun, let's run this down a little. I believe the poison pill previously was set at $1.12? Or 1.17? With current outlook what would a new poison pill be set at?
Thank you for the feedback.
I could be misremembering, but I believe Nasrat stated we are using some of that tech in today’s products.
Don’t misunderstand. I understand it’s not wise to invest further in ADT. Especially at this time. Only that it may have intrinsic value upon a sale. That was my only point I was asking about. Thanks for your responses
Of course the abuse deterrent technology has some value, versus the company not having the patents or technology at all, but I don't think very much at the moment. Value by investors won't be recognized until someone shows money can be made off abuse deterrent formulations. Not many companies are excited or working on abuse deterrent drug, but some are. The research shows that the case simply hasn't been made that its worthwhile to spend more on these products. Abuse deterrent drugs have not gained traction in the past 10 years at all. If one comes to market and starts making big bucks because doctors prescribe it over lower price alternatives then Elite may return to utilizing that technology. But until then I think Nasrat will wisely stay on the side lines. Elite doesn't have the money to create a market, we need to stick to pushing our way into established billion dollar markets.
From recent journal article by NIH on the issues in the abuse deterrent opioid market (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11162618/)
Hey, sport. You excited about how many commas I have in my stock account? Appreciate that! I've been laughing all the way to the bank as well! Let's laugh together. Ready? 🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣
Now, pay me my rent money.
I guess it depends on your styling. When the dependent clause is closely associated with the main clause, it is considered acceptable to omit the comma you are referencing. That's an awful lot of effort to defend a guy who hasn't used a punctuation mark since Obama was in office...
to be honest, I really don't know. I heard a whisper of a whisper of a name that was intriguing, but the things I hear have to be taken with some caution. Business, all of industries, are a smaller network than most on the outside would initially think. Rumors bounce around. I sift through them the best I can, but sometimes a rumor can be an intentional juke from the inside meant to throw off a competitor, and sometimes can just be envy from someone not in the know. Other times, it's just gums flapping from those who have had one too many and are trying to find a way to be in the room. For further clarity - I have heard absolutely nothing about past Epic partners. Perhaps that is because nothing is there, perhaps because that is the way they would want it.
Lazarus Elite
I replied to your post earlier and was expecting a feedback from you only to find out I didn't ask. lol
Gee whiz! Thank you for the encouragement and support 🙂
Thank you for your kind words and encouragement!
You’re correct, the adage of “all the eggs in one” may be dangerous so therefore I did put a small percentage in a few other stocks and a small amount in a money money fund for a rainy day… And if all things fail, I can dumpster dive for food in the future 😅
Hey Lazarus ,,,,,,,,,,,,,,,,,,,,,,, 😂
Been speculating right down the list since 2¢.
Which will we check off next ?
Upcoming ELTP Catalysts:
Going right down the line !!!!
X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Final Approval of New Manufacturing Facility/Expansion
__28. Double output of manufacturing and packaging facilities
__29. Launch approved generic Tylenol with Codeine $45 Million
__30. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__31. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
__33. Generic Vyvanse Approval and Launch
__34. Generic Concerta- FDA submission $1.2 BILLION
__35. $100 million in yearly revenue
__36. Generic OxyContin Tentative Approval $720 Million
__37. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__38.Launch generic OxyContin $720 Million
__39. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__40. European distribution - Dexcel partnership approval by Israeli Health
__41. $200 million in yearly revenue
__42. Patented Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__43. Undisclosed Mikah ANDA(s)
__44. Undisclosed ANDAs/NDAs
__45. Generic Concerta Approval and Launch
__46. DollarLand PPS
__47. Big Pharma bid
__48. UpList to the NASDAQ Exchange
__49. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
Bullish
LOFL...... Really
"punctuation , (comma) claims"
You forgot your comma. - ooops
Oh Did I miss something Did they get approval to launch it ?? Like I said speculation Unless of course that it gonna happen for sure I hope it does but until then you don’t know
Vyvance = DollarVille $1+
$5.1 Billion market with limited competitors
In extreme shortage.
ELTP
IMS market values are speculation ? LMAO
I believe you, lol
Add up the stock price 39 cents Your figures mean nothing It’s all speculation
I never sold Nor did I ever post I sold Get your facts straight Your to busy toppin off Its gonna get real lol
You don’t think it has a value if the company is acquired?
Hey genius We are pretty close to your market cap prediction Only 4 billion away lol Get real!!
Add up the market values:
1. Methotrexate $63.4M
2. Tylenol with Codeine $43M
3. Percocet $500M
4. Norco$477M
5. Methadone 30M
6. Vyvanse$5.10 Billion
7. Dopamine Agonist $12M
8. OxyContin $720M
9. Concerta $1.16 Billion
It’s About To Get Reeeeaal !!!
ELTP
What’s the matter Can’t handle a discussion
I wouldn’t even ask. When there is a material event, we will know. You wouldn’t divulge that publicly from a strategic standpoint.
We do know that Vyvanse market will take a big hit and same with generic oxy if we get that too. They will still be good markets, especially Vyvanse, but same song and dance as you shift from brand to generic.
Nasrat has put that on the backburner indefinitely and is instead grinding out billion dollar drugs. No drug company is making money off of abuse deterrent. That will only be profitable if the government forces it on consumers and I don't see them doing that.
Followers
|
1013
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
410002
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators jimr1717 mrwrn2010 NASDAQ2020 IB_ namtae Dr JoeBarducci |
Senior Moderator: IB_
Posted: 7/02/2024
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 64 | 85,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite |
Adderall XR | 1.56 B | On Market | 10 | Elite & Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 45 M | Approved in Launch Queue | 5 | ---------- |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Methotrexate | 63.4M | On Market | 8 | Elite |
Percocet | 500 M | Approved in Launch Queue | 14 | ---------- |
Norco | 477 M | Approved in Launch Queue | 12 | ---------- |
Methadone | 30 M | Approved in Launch Queue | 8 | ---------- |
OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | ??? | ---------- |
Vyvanse | 5.10 B | Filed with FDA - 21 Dec 2023 | 11 | ---------- |
Concerta | 1.16 B | In Development (Final Stages) | 8 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 | 56,625,128 | +65.79% | 20,108,631 | +464.56% |
2025 Q-1 | 18,803,063 | +109.39% | 3,864,056 | +144.00% |
2025 Q-2 | ||||
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |